Search research articles
Contact Us
Filters
Showing results (121-130 of 164) with videos related to
Page
of 17
Sort By:
Clinical Genitourinary Cancer
|
March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials
Patrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.
Cancer Chemotherapy and Pharmacology
|
April 11, 2014
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, et al.
Molecular Cancer Therapeutics
|
October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial
Marc Spielmann, Henri Roché, Thierry Delozier, et al.
Future Oncology (London, England)
|
June 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad, et al.
The Oncologist
|
December 2, 2016
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
Jean-Pascal Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 25, 2026
Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers
Engy Vigneron, Julie Vignau, Olivier Lowyck, et al.
Journal of Cardiovascular Pharmacology
|
February 23, 2013
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel
Pierre Maison-Blanche, Jan B Vermorken, Tuncay Goksel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 164) with videos related to
Sort By:
Page
of 17
Clinical Genitourinary Cancer
|
March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials
Patrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.
Cancer Chemotherapy and Pharmacology
|
April 11, 2014
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, et al.
Molecular Cancer Therapeutics
|
October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial
Marc Spielmann, Henri Roché, Thierry Delozier, et al.
Future Oncology (London, England)
|
June 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad, et al.
The Oncologist
|
December 2, 2016
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
Jean-Pascal Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 25, 2026
Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers
Engy Vigneron, Julie Vignau, Olivier Lowyck, et al.
Journal of Cardiovascular Pharmacology
|
February 23, 2013
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel
Pierre Maison-Blanche, Jan B Vermorken, Tuncay Goksel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
Page
of 17